AssureTech Secobarbital Strip, AssureTech Oxycodone Strip, AssureTech Secobarbital/Oxycodone Panel Dip, AssureTech Secobarbital/Oxycodone Quick Cup, AssureTech Secobarbital/Oxycodone Turn Key-Split Cup
Device Facts
| Record ID | K151211 |
|---|---|
| Device Name | AssureTech Secobarbital Strip, AssureTech Oxycodone Strip, AssureTech Secobarbital/Oxycodone Panel Dip, AssureTech Secobarbital/Oxycodone Quick Cup, AssureTech Secobarbital/Oxycodone Turn Key-Split Cup |
| Applicant | Assure Tech. Co., Ltd. |
| Product Code | DIS · Clinical Toxicology |
| Decision Date | Jun 4, 2015 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 862.3150 |
| Device Class | Class 2 |
Indications for Use
The AssureTech Secobarbital Strip test is an immunochromatographic assay for the qualitative determination of Secobarbital in human urine at a Cut-Off concentration of 300ng/mL. The test may yield preliminary positive results when prescription drug Secobarbital is ingested, even at or above therapeutic doses. There are no uniformly recognized drug levels for Secobarbital in urine. The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive. For in vitro diagnostic use only. The test is intended for over-the-counter and for prescription use. The AssureTech Oxycodone Strip test is an immunochromatographic assay for the qualitative determination of Oxycodone in human urine at a Cut-Off concentration of 100ng/mL. The test may yield preliminary positive results when prescription drug Oxycodone is ingested, even at or above therapeutic doses. There are no uniformly recognized drug levels for Oxycodone in urine. The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive. For in vitro diagnostic use only. The test is intended for over-the-counter and for prescription use. The AssureTech Secobarbital/Oxycodone Panel Dip test is an immunochromatographic assay for the qualitative determination of Secobarbital and Oxycodone in human urine at a Cut-Off concentration of 300ng/mL and 100 ng/mL, respectively. The test may yield preliminary positive results when prescription drug Secobarbital or Oxycodone is ingested, even at or above therapeutic doses. There are no uniformly recognized drug levels for Secobarbital or Oxyoodone in urine. The test provides only preliminary test results. A more specific alternative chemical must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive. For in vitro diagnostic use only. The test is intended for over-the-counter and for prescription use. The AssureTech Secobarbital/Oxycodone Quick Cup test is an immunochromatographic assay for the qualitative determination of Secobarbital and Oxycodone in human urine at a Cut-Off concentration of 300ng/mL and 100 ng/mL, respectively. The test may yield preliminary positive results when prescription drug Secobarbital or Oxycodone is ingested, even at or above therapeutic doses. There are no uniformly recognized drug levels for Secobarbital or Oxycodone in urine. The test provides only preliminary test results. A more specific alternative chemical must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive. For in vitro diagnostic use only. The test is intended for over-the-counter and for prescription use. The AssureTech Secobarbital/Oxycodone Turn Key-Split Cup test is an immunochromatographic assay for the qualitative determination of Secobarbital and Oxycodone in human urine at a Cut-Off concentration of 300ng/mL and 100 ng/mL. respectively. The test may yield preliminary positive results when prescription drug Secobarbital or Oxycodone is ingested, even at or above therapeutic doses. There are no uniformly recognized drug levels for Secobarbital or Oxycodone in urine. The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive. For in vitro diagnostic use only. The test is intended for over-the-counter and for prescription use.
Device Story
AssureTech drug test series (Strips, Panel Dips, Quick Cups, Turn-Key Split Cups) are lateral flow immunochromatographic assays for qualitative detection of Secobarbital and/or Oxycodone in human urine. Devices function via competitive binding: target drugs in urine compete with immobilized drug-conjugates for binding sites on monoclonal mouse antibody-coated particles. Absence of a test line indicates drug presence above cut-off; presence of a line indicates drug absence or levels below cut-off. A control line confirms proper flow. Used by lay users (OTC) or clinicians (prescription) for preliminary screening. Results are visual. Preliminary positive results require confirmatory testing via GC/MS. Benefits include rapid, point-of-care identification of potential drug use, facilitating clinical decision-making regarding further diagnostic or therapeutic steps.
Clinical Evidence
Bench testing only. Precision studies (n=50 per concentration per lot) across 25 days confirmed performance at cut-off levels. Interference and specificity studies evaluated cross-reactivity with various compounds. Method comparison study (n=80 clinical samples) compared device results to GC/MS. Lay-user study (n=1060) demonstrated high accuracy across diverse demographics and ease of use (Flesch-Kincaid Grade Level 7).
Technological Characteristics
Lateral flow immunochromatographic assay; competitive binding principle. Uses monoclonal mouse antibodies. Qualitative visual readout. Specimen: human urine. Cut-offs: 300ng/mL (Secobarbital), 100ng/mL (Oxycodone). Stable at 4-30°C for 24 months. No electronic components or software.
Indications for Use
Indicated for qualitative detection of Secobarbital (300ng/mL) and/or Oxycodone (100ng/mL) in human urine. Intended for over-the-counter and prescription use as a preliminary screening tool. Not for quantitative measurement. Positive results require confirmation by GC/MS.
Regulatory Classification
Identification
A barbiturate test system is a device intended to measure barbiturates, a class of hypnotic and sedative drugs, in serum, urine, and gastric contents. Measurements obtained by this device are used in the diagnosis and treatment of barbiturate use or overdose and in monitoring levels of barbiturate to ensure appropriate therapy.
Special Controls
*Classification.* Class II (special controls). A barbiturate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
Related Devices
- K033047 — ACON OXY ONE STEP OXYCODONE TEST STRIP AND ACON OXY ONE STEP OXYCODONE TEST DEVICE · ACON Laboratories, Inc. · Feb 17, 2004
- K143187 — Healgen Amphetamine Test (Strip, Cassette, Cup, Dip Card), Healgen Oxycodone Test (Strip, Cassette, Cup, Dip Card) · Healgen Scientific,, LLC · Jan 27, 2015
- K150179 — CR3 Keyless Split Sample Cup Oxycodone - Cannabinoids · Guangzhou Wondfo Biotech Co., Ltd. · Feb 25, 2015
- K181768 — AssureTech Panel Dip Tests, AssureTech Quick Cup Tests · Assure Tech. (Hangzhou) Co, Ltd. · Aug 20, 2018
- K100051 — INSTANT-VIEW MILTI-DRUG OF ABUSE URINE TEST (PANEL, CUP), INSTANT-VERDICT MULTI-DRUG OF ABUSE URINE TEST (PANEL, CUP) · Alfa Scientific Designs, Inc. · Jul 6, 2010
